European Society for Medical Oncology (ESMO)
Representing over 45,000 oncology professionals worldwide, ESMO is a reference for oncology education and information. Driven by a shared determination to secure the best possible outcomes for patients, ESMO is committed to standing by those who care about cancer through addressing the diverse needs of #ONEoncologycommunity, offering #educationforLIFE, and advocating for #accessiblecancerCARE.
European Society for Medical Oncology (ESMO)
Reporting from #ESMO23 in Madrid, Nicolas Girard discusses the results from two important studies on amivantamab in combination therapy for first-line treatment of patients with EGFR-mutated, advanced NSCLC
Abstracts discussed:
- LBA14 - Amivantamab Plus Lazertinib vs Osimertinib as First-line Treatment in Patients With EGFR-mutated, Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From MARIPOSA, a Phase 3, Global, Randomized, Controlled Trial, presented by B.C. Cho
- LBA5 - Amivantamab Plus Chemotherapy vs Chemotherapy as First-line Treatment in EGFR Exon 20 Insertion-mutated Advanced Non-small Cell Lung Cancer (NSCLC): Primary Results From PAPILLON, a Randomized Phase 3 Global Study, presented by Nicolas Girard
Simultaneous publication in the NEJM: www.nejm.org/doi/full/10.1056/NEJMoa2306441
https://www.youtube.com/watch?v=OpEVJ...
1 year ago | [YT] | 0
View 0 replies
European Society for Medical Oncology (ESMO)
Dr. Filippo Pietrantonio reports on key results from ESMO Congress 2023 on LBA10 - Sotorasib plus panitumumab versus standard-of-care for chemorefractory KRAS G12C-mutated metastatic colorectal cancer (mCRC): CodeBreak 300 phase 3 study
https://www.youtube.com/watch?v=4xCI2...
1 year ago | [YT] | 0
View 0 replies
European Society for Medical Oncology (ESMO)
Professor Ben Solomon reports on key results from ESMO Congress 2023 on LBA2 - ALINA: efficacy and safety of adjuvant alectinib versus chemotherapy in patients with early-stage ALK+ non-small cell lung cancer (NSCLC)
https://www.youtube.com/watch?v=pQoJJ...
1 year ago | [YT] | 0
View 0 replies
European Society for Medical Oncology (ESMO)
#ESMO23: Domenica Lorusso reports on key results from ESMO Congress 2023 on LBA38 - Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: A randomized, double-blind, phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study
https://www.youtube.com/watch?v=yrVmH...
1 year ago | [YT] | 0
View 0 replies
European Society for Medical Oncology (ESMO)
Reporting from AACR 2023, Robin Katie Kelley discusses the phase III KEYNOTE-966 study evaluating the combination of pembrolizumab with gemcitabine and cisplatin versus gem/cis alone in patients with previously untreated advanced biliary tract cancer. Longer overall survival and duration of response validate the role of immune checkpoint inhibition in combination with chemotherapy as first-line treatment option that improves outcomes in these patients. Simultaneously published in The Lancet. #AACR23
https://www.youtube.com/watch?v=URSZF...
2 years ago | [YT] | 0
View 0 replies
European Society for Medical Oncology (ESMO)
Adjuvant treatment for colon cancer: How to treat a stage III colon cancer with Andrés Cervantes. The combination of oxaliplatin and 5-FU provides a survival benefit over fluorouracil alone. However some patients will develop neurological toxicity, which may be severe and affect their quality of life. Evidence suggests that patients with low risk factors can be treated differently reducing the risk of side-effects.
From the OncologyPRO 'How To' video series: oncologypro.esmo.org/oncology-in-practice/practice…
2 years ago (edited) | [YT] | 0
View 0 replies
European Society for Medical Oncology (ESMO)
How to organise a department in #precisiononcology? Sonja Loges on key elements to creation and interaction with other teams, integrating data on genetic alterations in cancer care, & building precision oncology experiences with patients.
2 years ago | [YT] | 0
View 0 replies